The Durham, North Carolina-based startup's platform uses an image-based, tissue box-sized tool that cultures cells to capture long-term phenotypic behavior.
The companies will combine GenomOncology's GO Immuno-Oncology Workbench analysis software with Fluidigm's Advanta IO Gene Expression Assay.
Namocell has partnered with the two firms to distribute its cell dispensing tool in South Korea, the Netherlands, Belgium, and Luxembourg.
The firm will use the proceeds to accelerate commercialization and deployment of its microfluidic technology and for working capital purposes.
The firm will use the net proceeds to advance commercialization of its microfluidic technology and for general corporate purposes.
Tomy Digital Biology has agreed to distribute Namocell's microfluidic-based cell platforms in the Japanese market.
The funding totals up to $5.6 million over five years and will incorporate Talis' proprietary SlipChip technology.
The Alameda, California-based startup will use the funding to advance the commercialization of its rapid diagnostic platform for infectious diseases.
The firm's microfluidic-based technology collects and purifies genetic material, causing a complete PCR reaction that identifies diseases in liquid samples.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
NPR reports that with medical data being big business, some companies want to get patients involved.
The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.
In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.